(NASDAQ: CHRS) Coherus Oncology's forecast annual revenue growth rate of 40.77% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.6%, and it is also forecast to beat the US market's average forecast revenue growth rate of 11.65%.
Coherus Oncology's revenue in 2026 is $53,639,000.On average, 8 Wall Street analysts forecast CHRS's revenue for 2026 to be $9,125,330,719, with the lowest CHRS revenue forecast at $8,602,218,651, and the highest CHRS revenue forecast at $9,735,911,451. On average, 9 Wall Street analysts forecast CHRS's revenue for 2027 to be $14,344,861,024, with the lowest CHRS revenue forecast at $11,929,582,293, and the highest CHRS revenue forecast at $17,801,264,128.
In 2028, CHRS is forecast to generate $23,903,980,686 in revenue, with the lowest revenue forecast at $15,901,988,703 and the highest revenue forecast at $32,210,413,075.